ABIONYX Pharma announced that the Company's Phase 2b RACERS study in sepsis has been selected as a late-breaking clinical trial poster presentation at the 2023 American Society of Nephrology Annual Meeting taking place November 2-5, 2023 in Philadelphia, Pennsylvania.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.178 EUR | +14.15% | +11.98% | -8.54% |
14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
11/03 | Abionyx: reduced net loss in 2023 | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.54% | 35.87M | |
+4.34% | 111B | |
+11.17% | 105B | |
-12.07% | 22.34B | |
-3.76% | 21.93B | |
-6.08% | 18.59B | |
-36.52% | 18.12B | |
-10.15% | 16.96B | |
+3.40% | 13.7B | |
+36.38% | 12.45B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"